Loading...
Loading...
INVA| Name | Value |
|---|---|
| Revenues | 89.3M |
| Cost of Revenue | 23.1M |
| Gross Profit | 66.1M |
| Operating Expense | 28.6M |
| Operating I/L | 37.5M |
| Other Income/Expense | 23.7M |
| Interest Income | 4.8M |
| Pretax | 61.2M |
| Income Tax Expense | -0.3M |
| Net Income/Loss | 61.5M |
Innoviva, Inc. specializes in the development and commercialization of pharmaceuticals globally. Their key products include RELVAR/BREO ELLIPTA, ANORO ELLIPTA, and TRELEGY ELLIPTA, which are once-daily combination medicines for respiratory conditions. The company has a strategic partnership with Sarissa Capital Management LP and a collaboration agreement with Glaxo Group Limited to develop and market long-acting beta2 agonist (LABA) products for chronic obstructive pulmonary disease and asthma treatment.
